Education
About Us
Working with TipRanks
Follow Us
Inhibitor Therapeutics Inc. (INTI)
:INTI
INTI Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.03 - $0.10
Previous CloseN/A
Volume30.00
Average Volume (3M)3.01K
Market Cap
$9.43M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.85
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding172,323,550
10 Day Avg. Volume3,608
30 Day Avg. Volume3,010
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Inhibitor Therapeutics News
INTI FAQ
What was Inhibitor Therapeutics Inc.’s price range in the past 12 months?
Inhibitor Therapeutics Inc. lowest stock price was $0.03 and its highest was $0.10 in the past 12 months.
What is Inhibitor Therapeutics Inc.’s market cap?
Inhibitor Therapeutics Inc.’s market cap is $9.43M.
When is Inhibitor Therapeutics Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Inhibitor Therapeutics Inc.’s earnings last quarter?
Currently, no data Available
Is Inhibitor Therapeutics Inc. overvalued?
According to Wall Street analysts Inhibitor Therapeutics Inc.’s price is currently Overvalued.
Does Inhibitor Therapeutics Inc. pay dividends?
Inhibitor Therapeutics Inc. does not currently pay dividends.
What is Inhibitor Therapeutics Inc.’s EPS estimate?
Inhibitor Therapeutics Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Inhibitor Therapeutics Inc. have?
Inhibitor Therapeutics Inc. has 172,323,550 shares outstanding.
What happened to Inhibitor Therapeutics Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Inhibitor Therapeutics Inc.?
Currently, no hedge funds are holding shares in INTI
Company Description
Inhibitor Therapeutics Inc.
Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. It engages in the development of therapies for prostate and lung cancer utilizing SUBA-Itraconazole, an oral formulation of the drug itraconazole; and conducted a positive Phase 2b study of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida.
Inhibitor Therapeutics (INTI) Earnings & Revenues
Currently, no data available
Please return soon. This page is being updated.
Technical Analysis
Kiora Pharmaceuticals
―
Genprex
―
Cyclerion Therapeutics
―
Artelo Biosciences
―
Dogwood Therapeutics
―
Ownership Overview
14.98% Insiders
―
Mutual Funds
― Other Institutional Investors
85.02% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---